Business Wire

CA-ALKIRA

22.11.2021 10:02:09 CET | Business Wire | Press release

Share
Alkira Appoints Exclusive Networks as a Global Specialist Partner

Alkira Inc. has appointed Exclusive Networks, a global trusted cybersecurity specialist for digital infrastructure, as a distributor for its cloud networking as-a-service platform (CNaaS).

The deal makes Alkira’s CNaaS platform Cloud Services Exchange (CSX) available through Exclusive’s global partner ecosystem spanning 40 countries across five continents. It also underlines Exclusive’s commitment to growing its cloud portfolio in a market estimated by IDC to be on track for $1.3 trillion by 20251 .

Exclusive Networks (EXN), which posted gross sales of €2.9 billion in 2020, completed a successful Initial Public Offering and listing on Euronext Paris in September this year. The company has partnerships with some of the world’s largest and most successful cybersecurity, networking and cloud infrastructure vendors, including Fortinet, Nutanix, Palo Alto Networks, Rubrik and Sentinel One. It provides cybersecurity platforms, cloud solutions and associated value-add professional services through an extensive global partner network of specialist resellers, MSPs, CSPs, telcos and systems integrators.

Alkira has appointed Paul Couturier as Senior VP International to spearhead its expansion in the EMEA and APAC regions. Couturier is an IT industry veteran who has previously held senior management roles growing international markets for Efficient Networks, TippingPoint, Cyan, LightCyber and Palo Alto Networks. In his latest role, he managed IntSights from its European debut to its acquisition by Rapid 7.

Amir Khan, Co-Founder and Chief Executive Officer of Alkira, said: “Our vision is to simplify networking in the cloud era. As the CNaaS pioneer, Alkira has eliminated the complexities and costs of building and operating networks and seamlessly integrated cloud, multi-cloud and legacy systems – no hardware, no data center, no need to ship anything. Exclusive Networks is an ideal partner for Alkira, not only because it provides us with access to their first-class global network, but because we have a shared vision of an as-a-service future.”

Andy Travers, Executive Vice President, Worldwide Sales and Marketing for Exclusive Networks, said: “Our success has been built on bringing together best in class cybersecurity, networking and automation solutions. In the cloud era, the challenge for customers is how to integrate and manage these resources in an increasingly complex environment, while controlling costs and moving the business forward. With nothing more than a few mouse clicks, Alkira’s CNaaS enables secure hybrid cloud and multi-cloud networks to be set up in hours rather than months, and puts customers, not the big cloud providers, in the driver’s seat.

“Migration of enterprise applications to the cloud is set to double in the next two years, according to Gartner2 , so it seems inevitable that networking infrastructure will follow the same trend. Just as Alkira’s founders pioneered the SD-WAN market, we now believe they are showing the way in cloud networking.”

Alkira’s CNaaS platform simplifies provisioning, connectivity and end-to-end management of networks across cloud environments, including the integration of firewalls, IPS/IDS, and load balancers, as well as enhancing the capabilities of legacy SD-WAN solutions. It enables a flexible, unified approach to secure, high-performance networking in which customers only pay for the capacity they use, and the network automatically scales to meet changing patterns of usage and demand.

About Alkira

Alkira® developed the Network Cloud which enables enterprises to build and deploy a secure global unified multi-cloud network infrastructure as-a-service that delivers network connectivity, advanced network and services, and end-to-end visibility and governance. Alkira CSX seamlessly and securely connects branches, data centers, remote users and clouds. Alkira was founded by CEO Amir Khan, founder and former CEO of Viptela, and Atif Khan, CTO, former VP of integrated solutions and a member of the Viptela founding team. Alkira has raised $76M from Sequoia Capital, Kleiner Perkins, Koch Disruptive Technologies, LLC, and GV Capital (formerly Google Ventures). Learn more at www.alkira.com or follow us @AlkiraNet

(Alkira® and Alkira Cloud Services Exchange® are registered trademarks of Alkira, Inc. All other marks are the property of their respective owners.)

About Exclusive Networks

Exclusive Networks is a global trusted cybersecurity specialist for digital infrastructure helping to drive the transition to a totally trusted digital future for all people and organisations. Our distinctive approach to distribution gives partners more opportunity and more customer relevance. Our specialism is their strength – equipping them to capitalise on rapidly evolving technologies and transformative business models. The Exclusive Networks story is a global one with a services-first ideology at its core, harnessing innovation and disruption to deliver partner value. With offices in 40 countries and the ability to service customers in over 150 countries across five continents, Exclusive Networks has a unique ‘local sale, global scale’ model, combining the extreme focus and value of local independents with the scale and service delivery of a single worldwide distribution powerhouse. Learn more at www.exclusive-networks.com or follow us @EXN_Networks

1 IDC Forecasts Worldwide "Whole Cloud" Spending to Reach $1.3 Trillion by 2025
2 Market Guide to Cloud Networking Software, Gartner, May 2021

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye